A 1-year, single-center effectiveness review was conducted on the clinical outcomes in actively smoking peripheral arterial disease (PAD) patients treated with Grafix® for use in the treatment of refractory lower extremity ulcerations. Wound types included chronic ischemic and neuroischemic ulcerations and wounds of mixed venous and arterial etiology. Wounds were characterized by an average size of 4.6 cm2 and a previous duration of 53 weeks with a failure to respond to standard of care and other advanced treatment measures. Eighty percent of the patients were diabetic. Daily cigarette consumption for the patients ranged from ½ pack to > 1 pack per day, and the mean ankle brachial index for the group was 0.7. More than half of the patients were not candidates for revascularization procedures.
"Patients often times present with a variety of comorbid conditions that pose challenges to wound care providers. Some refractory wounds persist despite long term multidisciplinary efforts to promote timely closure. Options such as Grafix allow us to pursue management of these lower extremity ulcerations to the point of resolution. This is extremely valuable, especially in the high-risk diabetic population," said
Grafix is a cryopreserved placental membrane comprised of an extracellular matrix (ECM) rich in collagen, growth factors, and viable cells native to the tissue. Grafix is processed using Osiris' proprietary technology; it is flexible and conforming and designed for application directly to hard-to-treat acute and chronic wounds, including but not limited to diabetic foot ulcers, venous leg ulcers and thermal burns.
This press release may contain forward-looking statements. These forward-looking statements may generally be identified by the use of the words "may," "will," "expects," "anticipates," "believes," "estimates," and similar expressions, and involve a number of risks and uncertainties. For a variety of reasons, actual results may differ materially from those described in or contemplated by any such forward-looking statement. Examples of forward-looking statements may include, without limitation, statements regarding the anticipated efficiencies and advantages of products or services. Consequently, the reader is cautioned to consider all forward-looking statements in light of the risks to which they are subject.
For additional information, please contact:
Diane Savoie Osiris Therapeutics, Inc.(443) 545-1834 OsirisPR@Osiris.com
News Provided by Acquire Media